Adeona Pharmaceuticals’ Oral dnaJP1 Phase II Clinical Findings Presented At the American College of Rheumatology Annual Meeting

ANN ARBOR, Mich., Oct. 28, 2008 (GLOBE NEWSWIRE) -- Adeona Pharmaceuticals, Inc. (AMEX:AEN), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of autoimmune and central nervous system diseases, announced today that its scientific collaborator presented new findings from a 160-patient, double-blind, placebo-controlled phase II clinical trial using oral dnaJP1 for the treatment of rheumatoid arthritis (RA) at the American College of Rheumatology (ACR) annual meeting in San Francisco, CA.